Takeda Pharmaceutical (TSE: 4502, NYSE: TAK) announced Phase 3 clinical trial results showing its investigational drug zasocitinib outperformed deucravacitinib in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE